Global Leading Market Research Publisher Global Info Research announces the release of its latest report *“Minimal Residual Disease (MRD) Testing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”.* Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Minimal Residual Disease (MRD) Testing market, including market size, share, demand, industry development status, and forecasts for the next few years.
For oncologists treating hematologic malignancies (leukemia, lymphoma, multiple myeloma) and solid tumors, detecting residual cancer cells after treatment (chemotherapy, radiation, stem cell transplant) is critical for predicting relapse and guiding maintenance therapy. Minimal Residual Disease (MRD) testing identifies low levels of malignant cells (<0.01%) not detectable by conventional morphology. Technologies include flow cytometry (multiparameter, detects aberrant immunophenotypes), polymerase chain reaction (PCR, detects clonal gene rearrangements, translocations), next-generation sequencing (NGS, high-sensitivity detection of somatic mutations, clonal diversity), and liquid biopsies (circulating tumor DNA, ctDNA, for solid tumors). The market is driven by increasing adoption of MRD-guided treatment (risk stratification, early intervention), FDA approvals for MRD as surrogate endpoint (clinical trials), and rising leukemia/lymphoma incidence.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5985721/minimal-residual-disease–mrd–testing
Market Valuation & Growth Trajectory (2026-2032)
The global market for Minimal Residual Disease (MRD) Testing was estimated to be worth approximately US$ 1.85 billion in 2025 and is projected to reach US$ 4.25 billion by 2032, growing at a CAGR of 12.6% from 2026 to 2032 (Source: Global Info Research, 2026 revision). This growth reflects increasing MRD integration into clinical guidelines (NCCN, ESMO), test menu expansion (solid tumors), and reimbursement improvements. Key regions: North America (45% of sales), Europe (25%), Asia-Pacific (20%, China, Japan), Rest of World (10%). Average test cost: flow cytometry $200-500, PCR $300-800, NGS $500-2,000, liquid biopsy $1,000-5,000. Insurance coverage: Medicare, private payers for leukemia, lymphoma, multiple myeloma. Limited for solid tumors (research use). Sensitivity: flow cytometry 10^-4 (0.01%), PCR 10^-5-10^-6 (0.001-0.0001%), NGS 10^-5-10^-6, liquid biopsy variable (depends on tumor shedding). Minimal residual disease negative status associated with longer progression-free survival (PFS), overall survival (OS). Used in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and emerging in solid tumors (breast, colon, lung).
Exclusive Observer Insights (Q1-Q2 2026): Key market trends include: (1) clonoSEQ (Adaptive Biotechnologies) FDA-approved NGS MRD assay for ALL, MM, CLL; (2) liquid biopsy for ctDNA MRD in solid tumors (Signatera, Natera; Guardant Reveal); (3) digital PCR (dPCR) for higher accuracy; (4) AI/ML for flow cytometry data analysis; (5) standardized reporting (MRD level, limit of detection). Flow cytometry: most common, rapid (hours), lower cost, detects aberrant immunophenotype. Requires fresh bone marrow aspirate (invasive). Sensitivity 0.01% (10^-4). PCR: for specific genetic markers (BCR-ABL, MLL rearrangements, IG/TCR clonality). High sensitivity (10^-6), quantitative (log reduction). NGS: broader detection (multiple clones), high sensitivity, detects emergent resistant clones. Liquid biopsy: non-invasive (blood draw), for solid tumors (detect ctDNA). Sensitivity lower (depends on tumor type, stage). MRD testing guides therapy: MRD-positive after induction (ALL) escalate treatment (blinatumomab, transplant). MRD-negative- may de-escalate (reduce toxicity). Serial monitoring every 3-6 months.
Key Market Segments: By Type, Application, and Technology
Major players include Sysmex Corporation (Japan, flow cytometry), Natera (US, Signatera), Asuragen (US, now Bio-Techne), Quest Diagnostics (US), Mission Bio (US, Tapestri), LabCorp (US), Guardant Health (US, Guardant Reveal), NeoGenomics Laboratories (US), ARUP Laboratories (US), Opko Health (US, 4Kscore), and Bio-Rad Laboratories (US, QX600 dPCR).
Segment by Type (Technology):
- Flow Cytometry – Largest volume (approx. 40% of market). Lower cost, rapid. For hematologic malignancies (leukemia, lymphoma). Requires fresh bone marrow. Sensitivity 10^-4.
- Polymerase Chain Reaction (PCR) – Second-largest (approx. 30% of market). High sensitivity (10^-6), quantitative. For specific genetic targets (BCR-ABL, IG/TCR). Cost moderate.
- Next-generation Sequencing (NGS) – Fastest-growing (approx. 20% of market, CAGR 18%). High sensitivity, broad clonal detection. For both hematologic and solid tumors. Higher cost.
- Liquid Biopsies – Emerging (approx. 10% of market, rapid growth). Non-invasive (blood), for solid tumors. Sensitivity improving.
Segment by Application (End-User Sector):
- Hospitals – Largest segment (approx. 50% of testing). Academic medical centers, cancer centers. In-house flow cytometry, PCR. Reference labs for NGS, liquid biopsy. Higher volume.
- Specialty Clinics – Second-largest (approx. 30% of testing). Oncology clinics, hematology practices. Send-out to reference labs (Quest, LabCorp, NeoGenomics).
- Research Institutions – Approx. 20% of testing. Clinical trials (MRD as endpoint), translational research. NGS, liquid biopsy.
Industry Layering: MRD Testing Technologies
| Technology | Sensitivity | Turnaround Time | Sample Type | Cost | Applications | Market Share |
|---|---|---|---|---|---|---|
| Flow cytometry | 10^-4 (0.01%) | 1-2 days | Bone marrow (fresh) | $200-500 | ALL, AML, CLL, MM, NHL | 40% |
| PCR (qPCR, dPCR) | 10^-5-10^-6 | 2-5 days | Bone marrow, blood, tissue | $300-800 | BCR-ABL (CML), IG/TCR (ALL), gene fusions | 30% |
| NGS (clonoSEQ) | 10^-5-10^-6 | 7-14 days | Bone marrow, blood | $500-2,000 | ALL, MM, CLL, AML | 20% (growing) |
| Liquid biopsy (ctDNA) | Variable (0.0001-1%) | 7-14 days | Blood (plasma) | $1,000-5,000 | Solid tumors (breast, colon, lung) | 10% (emerging) |
Technological Challenges & Market Drivers (2025-2026)
- Standardization – MRD results vary across labs (cutoffs, methodology). EuroFlow consortium (flow cytometry), EuroMRD (PCR, NGS). CLIA certification, proficiency testing.
- Tumor heterogeneity – Clonal evolution, emergence of resistant clones. NGS detects multiple clones (better than PCR). Liquid biopsy may miss non-shedding tumors.
- Reimbursement – Medicare covers MRD for ALL, CLL, MM (NCD). Private payers follow. Solid tumor MRD limited coverage (investigational). Clinical utility trials ongoing.
- Turnaround time – NGS 7-14 days (slow for treatment decisions). Faster flow cytometry (1-2 days) for induction response. Point-of-care MRD emerging.
Real-World User Case Study (2025-2026 Data):
A large academic cancer center (500 ALL patients/year) switched from flow cytometry MRD (sensitivity 10^-4, 1-day) to NGS (clonoSEQ, sensitivity 10^-6, 7-day) for post-induction monitoring. Baseline (flow): 30% MRD-positive (0.01-0.1%), relapse rate 50%. After NGS (2025):
- MRD detection: increased to 45% positive (10^-5-10^-6). Ultra-low MRD better predicts relapse.
- Treatment escalation: additional chemotherapy (blinatumomab) for NGS-positive patients (30%). Relapse rate reduced to 30%.
- Cost: NGS $800 vs flow $300 (+$500). 500 patients/year = $250k incremental cost. But reduced relapse (15 fewer relapses, salvage cost $100k each) = $1.5M savings. Net saving $1.25M.
- Result: Adopted NGS as standard.
Exclusive Industry Outlook (2027–2032):
Three strategic trajectories by 2028:
- NGS/high-sensitivity tier (Natera, Adaptive, Guardant, Mission Bio) — 15-18% CAGR. $500-5,000. Growing.
- Flow cytometry/PCR tier (Sysmex, Asuragen, Quest, LabCorp, NeoGenomics, ARUP, Opko, Bio-Rad) — 10-12% CAGR. $200-800.
- Solid tumor liquid biopsy tier — 20-25% CAGR (fastest-growing). $1,000-5,000. Emerging.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
